Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges
A concise report featuring insights from the prominent thought leaders of Biologics 2024
Exploring Innovative Approaches Throughout the CGT Development Journey
A Concise Report Featuring Insights From The Prominent Thought Leaders Of Cell UK
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Oligo Chemistry
The Complex Case of Antisense Oligonucleotides
We gain a glimpse into what the landscape of antisense oligonucleotides looks like today, from computational representations to protein purification.
MIT Team Create AI-Generated Universal COVID Vaccine
New COVID variants are still a significant risk; but could an AI-generated universal COVID vaccine be the key to overcoming this?
Antibody & Protein Engineering
How AI is Changing the Game for Protein Design
Researchers at the University of Washington have succeeded in using machine learning to synthesise artificial enzymes which are actually functional in cells.
Antibody & Protein Engineering
Computational Tools and AI/ML for Antibody Engineering
Opinion leaders from Merck and AbbVie discuss how antibody-based molecular engineering is developing with new AI/ML technologies.
NextGen Therapeutics
Biocon’s Biosimilar Difficulties: Successive FDA Rejections Don’t Inspire Hope
Biocon suffer another FDA rejection due to data and manufacturing concerns, this time for their bevacizumab biosimilar.
The EMA’s Vaccines Working Party: The New Authority on Vaccines
The Vaccines Working Party was established last year by the EMA, but what are its main tasks, and how are they looking to achieve them?
Antibody & Protein Engineering
POLIVY vs ODAC: Can the Cancer Drug Score Another Indication?
The Oncologic Drugs Advisory Committee are preparing to weigh in on whether the FDA should grant another indication for Roche’s POLIVY.
Antibody & Protein Engineering
No More Hold-Ups: FDA Lifts Hold on Parkinson’s Drug
The FDA has repealed the hold placed on clinical trials for the Parkinson’s drug IkT-148009, which began in November.
The Race for an RSV Vaccine Approval
Things are heating up in the race to pinch the first FDA approval of an RSV vaccine, as Moderna joins Pfizer and GSK in the running.
Antibody & Protein Engineering
FDA Grant Approval for Alzheimer's Drug Leqembi
The US regulators have approved Eisai and Biogen’s Alzheimer’s drug, lecanemab, a “landmark” moment for the disease.
Peptide Chemistry
The Future of Peptide Chemistry and Sustainability
The peptide market is continually developing, but how are manufacturers responding to its new requirements and altering the landscape of peptide manufacturing?
NextGen Therapeutics
Regeneron’s New Bispecific: A Toxic Success?
Regeneron announced that their bispecific odronextamab had the highest recorded complete response rate for follicular lymphoma, but the therapeutic antibody’s safety profile has thrown up several concerns.